778 related articles for article (PubMed ID: 17450683)
1. [Leukotrienes: potential therapeutic targets in cardiovascular diseases].
Bäck M
Bull Acad Natl Med; 2006 Oct; 190(7):1511-8; discussion 1518-21. PubMed ID: 17450683
[TBL] [Abstract][Full Text] [Related]
2. Functional characterisation of receptors for cysteinyl leukotrienes in smooth muscle.
Jonsson EW
Acta Physiol Scand Suppl; 1998 Mar; 641():1-55. PubMed ID: 9597121
[TBL] [Abstract][Full Text] [Related]
3. Studies of receptors and modulatory mechanisms in functional responses to cysteinyl-leukotrienes in smooth muscle.
Bäck M
Acta Physiol Scand Suppl; 2002 Feb; 648():1-55. PubMed ID: 11913222
[TBL] [Abstract][Full Text] [Related]
4. Leukotriene receptors in atherosclerosis.
Bäck M; Hansson GK
Ann Med; 2006; 38(7):493-502. PubMed ID: 17101540
[TBL] [Abstract][Full Text] [Related]
5. Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery.
Trandafir CC; Nishihashi T; Ji X; Wang A; Kurahashi K
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1027-33. PubMed ID: 16445567
[TBL] [Abstract][Full Text] [Related]
6. [Leukotrienes as inflammation mediators].
Woszczek G; Pawliczak R; Kowalski ML
Postepy Hig Med Dosw; 2003; 57(5):593-610. PubMed ID: 14737972
[TBL] [Abstract][Full Text] [Related]
7. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends.
Capra V; Thompson MD; Sala A; Cole DE; Folco G; Rovati GE
Med Res Rev; 2007 Jul; 27(4):469-527. PubMed ID: 16894531
[TBL] [Abstract][Full Text] [Related]
8. Leukotriene modifiers in the treatment of cardiovascular diseases.
Riccioni G; Capra V; D'Orazio N; Bucciarelli T; Bazzano LA
J Leukoc Biol; 2008 Dec; 84(6):1374-8. PubMed ID: 18794213
[TBL] [Abstract][Full Text] [Related]
9. Effects of synthetic peptido-leukotrienes on bone resorption in vitro.
Garcia C; Qiao M; Chen D; Kirchen M; Gallwitz W; Mundy GR; Bonewald LF
J Bone Miner Res; 1996 Apr; 11(4):521-9. PubMed ID: 8992883
[TBL] [Abstract][Full Text] [Related]
10. Functional studies of leukotriene receptors in vascular tissues.
Walch L; Norel X; Gascard JP; Brink C
Am J Respir Crit Care Med; 2000 Feb; 161(2 Pt 2):S107-11. PubMed ID: 10673237
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells.
Kamohara M; Takasaki J; Matsumoto M; Matsumoto Si ; Saito T; Soga T; Matsushime H; Furuichi K
Biochem Biophys Res Commun; 2001 Oct; 287(5):1088-92. PubMed ID: 11587533
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids.
Rubin P; Mollison KW
Prostaglandins Other Lipid Mediat; 2007 May; 83(3):188-97. PubMed ID: 17481554
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor agonists differentially regulate cysteinyl-leukotriene receptor 1 expression and function in human dendritic cells.
Thivierge M; Stankova J; Rola-Pleszczynski M
J Allergy Clin Immunol; 2006 May; 117(5):1155-62. PubMed ID: 16675346
[TBL] [Abstract][Full Text] [Related]
14. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism.
Pedersen KE; Bochner BS; Undem BJ
J Pharmacol Exp Ther; 1997 May; 281(2):655-62. PubMed ID: 9152370
[TBL] [Abstract][Full Text] [Related]
15. The ACh-induced contraction in rat aortas is mediated by the Cys Lt1 receptor via intracellular calcium mobilization in smooth muscle cells.
Mazzetti L; Franchi-Micheli S; Nistri S; Quattrone S; Simone R; Ciuffi M; Zilletti L; Failli P
Br J Pharmacol; 2003 Feb; 138(4):707-15. PubMed ID: 12598425
[TBL] [Abstract][Full Text] [Related]
16. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics.
Singh RK; Gupta S; Dastidar S; Ray A
Pharmacology; 2010; 85(6):336-49. PubMed ID: 20516735
[TBL] [Abstract][Full Text] [Related]
17. Cysteinyl leukotriene receptors.
Evans JF
Prostaglandins Other Lipid Mediat; 2002 Aug; 68-69():587-97. PubMed ID: 12432945
[TBL] [Abstract][Full Text] [Related]
18. The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets?
Sharma JN; Mohammed LA
Inflammopharmacology; 2006 Mar; 14(1-2):10-6. PubMed ID: 16835707
[TBL] [Abstract][Full Text] [Related]
19. Endothelium-dependent vascular responses induced by leukotriene B4.
Bäck M; Sakata K; Qiu H; Haeggström JZ; Dahlén SE
Prostaglandins Other Lipid Mediat; 2007 May; 83(3):209-12. PubMed ID: 17481557
[TBL] [Abstract][Full Text] [Related]
20. Leukotriene C4 induces bronchoconstriction and airway vascular hyperpermeability via the cysteinyl leukotriene receptor 2 in S-hexyl glutathione-treated guinea pigs.
Yonetomi Y; Sekioka T; Kadode M; Kitamine T; Kamiya A; Matsumura N; Fujita M; Kawabata K
Eur J Pharmacol; 2015 May; 754():98-104. PubMed ID: 25704617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
